RxDoctor Payments Data

Samuel Abbate

Endocrinology, Diabetes & Metabolism · Wasilla, AKNPI 1316953409

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.5% of the total across 112 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $825 and has fallen 60.3% since, to $327 in 2021.

$1,752in general payments, 2019–2025

Across 112 payments — averaging $15.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$307
  • Lilly USA, LLC$290
  • Novo Nordisk$213
  • Amgen$184
  • Merck$152
  • Sanofi-aventis U.S. LLC$147
  • plus $459 from 15 others

What the payments were for

  • Food & beverage$1,72598%
  • Education$272%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few endocrinology, diabetes & metabolism providers in Alaskato place this figure against a meaningful peer group, so we don't.

Other endocrinology, diabetes & metabolism in Wasilla

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →